HIM
PRLD icon

Hillsdale Investment Management’s Prelude Therapeutics PRLD Stock Holding History

Hillsdale Investment Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$434K Buy
+81,400
New +$354K 0.01% 456

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Hillsdale Investment Management's PRLD Position: Q2 2026 in Review

Hillsdale Investment Management opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 81,400 shares worth $434K. The stake represents 0.01% of the portfolio and ranks #456 among its holdings.

75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Hillsdale Investment Management held 81,400 shares of Prelude Therapeutics worth $434K as of Q2 2026.
  • Prelude Therapeutics was a new Hillsdale Investment Management position in Q2 2026.
  • Prelude Therapeutics made up 0.01% of Hillsdale Investment Management's portfolio in Q2 2026, its #456 holding.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.